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Abstract 
The sgc8c aptamer is a 41-base DNA oligonucleotide that binds to leukaemia cells with high 
affinity and specificity. In this work we examined the utility of this aptamer as both a 
delivery vehicle and an active targeting agent for an inert platinum complex [(1,10-
phenathroline)(ethylenediamine)platinum(II)]2+. The aptamer forms a stem-and-loop 
confirmation as determined by circular dichroism. This conformation is adopted in both 
water and phosphate buffered saline solutions. The metal complex binds to the aptamer 
through intercalation into the aptamer’s double helical stem with a binding constant of 
approximately 4.3 × 104 M-1. Binding of the metal complex to the aptamer had a significant 
effect on the aptamer’s global conformation, and increased its melting temperature by 28 
oC possibly through lengthening and stiffening of the aptamer stem. The effect of the 
aptamer on the metal complex’s cytotoxicity and cellular uptake was determined using in 
vitro assays with the target leukaemia cell line CCRF-CEM and the off-target ovarian cancer 
cell lines A2780 and A2780cp70. The aptamer has little inherent cytotoxicity and when used 
to deliver the metal complex results in a significant decrease in the metal complex’s 
cytotoxicity and uptake. The reason(s) for the poor uptake and activity may be due to the 
change in aptamer conformation which affects its ability to recognise leukaemia cells. 
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1. Introduction 
Platinum-based chemotherapy agents represent one of the most important classes of drug 
used to combat a range of human cancers [1, 2].  Whilst effective, the six drugs currently on 
the market display poor selectivity for cancers compared with other rapidly dividing cells 
within the human body.  As a result there has been enormous interest in the development 
of delivery vehicles for platinum drugs, which are able to either passively or actively target 
solid tumours, whilst sparing normal tissue from damage [3-5]. 
 
Aptamers are oligonucleotide-based recognition molecules which can be short single 
stranded DNA, RNA, or modified nucleic acid fragments (i.e. locked nucleic acid) [6]. These 
molecules are able to recognise proteins and peptides expressed on the surface of cells in a 
manner similar to antibodies. Aptamers with appropriate selectivity can be rapidly 
generated through an in vitro process known as Systematic Evolution of Ligand by 
EXponential enrichment (SELEX) and offer reduced immunogenicity, good tumour 
penetration, rapid uptake and clearance, as active targeting groups for drug delivery [7]. In 
particular, they have the potential to act as cancer targeting molecules as they are able to 
recognise and bind proteins that are over-expressed on the surface of cancerous cells [8]. 
Aptamers can be better targeting agents compared with essential small molecules, like 
folate or oestrogen, because of their high cell selectivity, are simpler to synthesise and 
produce than antibodies, have good stability in storage, and have little or no 
immunogenicity. 
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To date aptamers have been used successfully as active targeting agents on the outside of 
liposome- and micelle-like vehicles containing platinum drugs. Because the platinum drugs 
are sequestered within the delivery vehicle they do not interact or irreversibly bind to the 
guanosine and adenosine bases of the aptamer [9-12]. The need for both a separate 
delivery vehicle and a conjugated targeting aptamer is complicated to construct and control, 
with respect to particle size and consistent drug loading. We were therefore interested to 
see if it was possible to discard the delivery vehicle component of the system and instead 
use the aptamer as both the cancer targeting agent and the delivery vehicle simultaneously. 
An aptamer of particular potential for this application is the sgc8c aptamer [13]. This DNA-
based aptamer consists of 41 bases and is able to recognise and bind T-cell acute 
lymphoblastic leukaemia cells with a binding constant of 0.78 nM [13].  
Unfortunately, “normal” platinum drugs, like cisplatin and carboplatin, which form 
coordination bonds with DNA after aquation of their labile ligands, cannot be used in this 
manner. These drugs can form irreversible bonds with N7 atom of guanosine and adenosine 
bases in the aptamer, and therefore not go on to bind cellular DNA. Instead, platinum 
anticancer complexes which are coordinately saturated with non-labile amine groups are 
needed. In the last decade several families of platinum complexes that fit this description 
have been developed and which are able to reversibly bind to double helical DNA [14-16]. 
These platinum(II) complexes have displayed very high cytotoxicity, and are able to 
overcome drug-resistance in a variety of different cancer cell lines [15]. An example is a 
trinuclear platinum complex with bridging 1,6-diaminohexane ligands developed by Farrell 
and co-workers. With its 8+ charge it is highly water soluble and binds strongly, but 
reversibly, to double stranded DNA [17]. Another inert platinum complex which has 
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displayed potential is (5,6-dimethyl-1,10-phenanthroline)(1S,2S-
diaminocyclohexane)platinum(II) (56MESS) which was developed by Aldrich-Wright [18-20]. 
The highly aromatic phenanthroline-based complex is able to intercalate into double 
stranded DNA, although its mechanism of action is not thought to be related to its DNA 
binding [21].  
 
In this paper we report the first attempted use of an aptamer to act simultaneously as both 
a delivery vehicle and as an active cancer targeting agent. We examine the aptamer’s 
tertiary structure by circular dichroism and 1H NMR, the binding of the metal complex 
[(1,10-phenanthroline)(ethylenediamine)platinum(II)]2+ (PHENEN) to the aptamer, and the 
effect of the aptamer on the on the metal complex’s cytotoxicity and uptake in the on-
target CCRF-CRM leukaemia cell line and the off-target A2780 and A2780/cp70 ovarian 
carcinoma cell lines. 
 
2. Experimental 
2.1 Materials 
PHENEN was made as previously reported [20]. Potassium tetrachloroplatinate, 
ethylenediamine, 1,10-phenanthroline, monosodium phosphate, disodium phosphate, 
sodium chloride, dimethylsulfoxide, methanol, diethyl ether, ethanol and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma 
Aldrich. The sgc8c aptamer was purchased from Alpha DNA, Canada. The sequence of the 
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sgc8c as reported by Shangguan et al is: 5’-ATC TAA CTG CTG CGC CGC CGG GAA ATT ACT 
GTA CGG TTA GA [13]. Prior to use the aptamer was annealed by dissolving it in water and 
heating to 90 oC in a water bath. It was then allowed to slowly cool to room temperature 
over a period of several hours, whilst still in the water bath. RMPI 1640 medium, phosphate 
buffered saline (PBS), trypsin 2.5%, fetal bovine serum, glutamine were purchased from 
Invitrogen. Glycine buffer chemicals were purchased from Fischer Scientific. The ovarian cell 
lines A2780 and cisplatin resistant derivative a2780/cp70 were obtained from Fox and Chase 
Cancer Centre, Philadelphia and the leukaemia cell line CCRF-CEM was obtained from the 
American Type Culture Collection. RPMI medium was modified by addition of 1% (5 mL) 
glutamine and 10% (50 mL) fetal bovine serum. All solutions were prepared using water 
obtained from a Millipore Direct-Q water purification system.  
 
2.2 Preparation of Buffers 
PBS solutions (10 mM and 100 mM) were produced using a standard method. A 100 mM 
stock solution of NaCl was prepared in water. This stock solution was then used for the 
preparation of both 10 mM and 100 mM phosphate solutions, using a mixture of 
monosodium phosphate and disodium phosphate. For the 10 mM NaCl phosphate buffer, 
monosodium phosphate (1.8 g) in NaCl stock solution (150 mL) was combined slowly with 
disodium phosphate (2.1 g) in NaCl stock solution (150 mL) while the pH of the solution was 
measured until a pH of 7 was attained. This method was employed in the same manner for 
the preparation of the 100 mM buffer solution. Glycine buffer was prepared by the addition 
of glycine (0.1 M) to NaCl (0.1 M) with the pH adjusted to 10.5 using NaOH (0.1 M). 
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2.3 Instrumental techniques 
2.3.1 UV-Vis spectroscopy 
UV-visible spectrometry was carried out on a Cary 50 Bio spectrophotometer between 200-
700 nm, with the scan speed set to medium and using a 1 cm quartz cuvette. All samples 
were analysed at room temperature. 
 
2.3.2 NMR spectroscopy 
1H NMR spectra of the free sgc8c aptamer, the aptamer bound with PHENEN and 2D nuclear 
overhauser effect spectroscopy (NOESY) of the free aptamer were obtained on either a 400 
MHz or 600 MHz Bruker Avance spectrometer in D2O at 27 
oC with 128-256 scans. 
 
2.3.3 CD spectrophotometry 
All CD spectra were measured in a 2 mm quartz cuvette using a Chirascan CD spectrometer 
at 25 oC. An air background was run followed by a blank sample of water with 2 repeats 
prior to sample analysis. All samples were prepared to a concentration of 3.4 µM, confirmed 
by UV, in water, 10 mM or 100 mM PBS solutions.  Spectra were recorded from 200-350 nm 
with 5 repeats, at a step value of 0.5 nm and a time of 3 seconds per step.  The N2 carrier 
gas flow for the sample was 2 mL min-1. The binding constant of PHENEN to the sgc8c 
aptamer was determined using equation 1, where E is the measured ellipticity at each 
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titration point, E0 is the ellipticity when no PHENEN has been added, E∞ is the maximum 
ellipticity, [PHENEN] is the concentration of the metal complex at each titration point and k 
is the binding constant: 
Equation 1   
[PHENEN]k1
[PHENEN]k
1)/E(E1E/E 00

   
2.3.4 Thermal UV-Vis Spectrometry  
Thermal UV spectra were obtained using a Cary spectrophotometer. Spectra were recorded 
for 4 samples simultaneously using a moveable cuvette holder, at a fixed wavelength of 260 
nm over the temperature range 10-80 oC. Samples were measured in 1 cm quartz cuvettes, 
with the melting temperature (Tm) recorded for each sample. Four aptamer samples were 
prepared to a concentration of 3.4 µM in 10 mM PBS solution with 0, 1, 2 and 3 equivalents 
of PHENEN being added, respectively. Four heating and 4 cooling cycles were run and the 
average of these results obtained for each PHENEN titration point. 
 
2.4 In Vitro Testing 
2.4.1 Cytotoxicity 
The cytotoxicity of PHENEN and the sgc8c aptamer were measured using growth inhibition 
MTT assays and is reported as their IC50 concentration in micromolar (µM). Cytotoxicity was 
determined in the leukaemia cell line CCRF-CEM, and the ovarian cell lines A2780 and 
A2780/cp70 and compared with cisplatin. In all assays PHENEN was dissolved in water and 
diluted to the desired concentration (100 µM) using modified RPMI 1640 medium. Cisplatin 
was dissolved in 3% DMSO/97% RPMI medium and again diluted to the desired 
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concentration (100 µM) using modified RPMI 1640 medium. For assays carried out in the 
ovarian cell lines a cell density of 1 x 103 per well was selected for both the A2780 and 
A2780/cp70 lines and a cell density of 2 x 105 per well for the CCRF-CEM line was used. The 
ovarian cell lines were grown into flat 96 well plates and incubated for 48 h. Following this, 
the medium was removed and replaced with either PHENEN or cisplatin solutions at 
concentrations between 0 to 100 µM. The plates were further incubated for 24 h before the 
medium and drug were removed, replaced by fresh medium and incubated for a further 48 
h. Plates were then fed with fresh medium and MTT solution (50 µL), wrapped in tinfoil and 
incubated for 4 h. The medium and MTT were removed from the wells leaving the purple 
MTT-formazan crystals. These were dissolved by addition of DMSO (200 µL) and glycine 
buffer (25 µL). Plates were then read by their absorbance at 570 nm with the resulting dose-
response curve displaying absorbance (y-axis) with respect to drug concentration in µM (x-
axis). The same procedure was employed for measurement of drug cytotoxicity in the 
leukaemia cell lines but as they were non-adherent, circular bottomed 96 well plates were 
used, with these being centrifuged at 1,000 g for 5 min to pellet cells prior to removal of 
medium. Removal of medium was carried out using a fine gauge hypodermic needle (24 G) 
to prevent removal of the cell pellet.  All incubations were undertaken in a 5% CO2 
humidified atmosphere at 37 oC. 
 
 
2.4.2 Cell Uptake 
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Selectivity and uptake of PHENEN and PHENEN bound sgc8c aptamer were measured in on-
target leukaemia CCRF-CEM and the off-target ovarian A2780 and A2780/cp70 cell lines. For 
drug uptake in the adherent ovarian cell lines a cell density of 1x106 cells/well was used with 
incubation overnight at 37 oC in a 10% CO2 humidified atmosphere. Following incubation, 
the medium was replaced with either fresh medium or medium containing either cisplatin, 
PHENEN or PHENEN bound sgc8c aptamer, at a concentration of 10 µM, before the cells 
were incubated for another 2 or 4 h. The medium/drug solutions were then removed and 
the ovarian cells washed with ice cold PBS and lysed by adding 215 µL of nitric acid to each 
well. For the non-adherent CCRF-CEM leukaemia cell line a density of 2 x 106 cells in 0.5 mL 
was added into microfuge tubes. To this, 0.5 mL of medium or medium containing either 
cisplatin, PHENEN or PHENEN bound sgc8c aptamer, all at a concentration of 20 µM, was 
added and the tubes incubated at 37 oC for 2 or 4 h with constant mixing. The tubes were 
then centrifuged at 300 g for 4 min to pellet the cells allowing the medium to be removed. 
Cells were washed with ice cold PBS (1 mL) and centrifuged again at 300 rpm for 4 min 
before the PBS was removed and the cells were digested in 215 µL nitric acid. 
The digested leukaemia and ovarian cells were then collected in a microfuge tube and 
incubated overnight at 65 oC on a heating block. The digest (50 µL) was then diluted 100-
fold using water and 0.1% Triton-X100 anionic surfactant. The platinum content of each 
sample was then determined using inductively coupled plasma mass spectrometry (ICP-MS) 
and the uptake recorded as picomoles of platinum per 106 cells for the mean ± standard 
error of the mean (SEM) of three wells.  
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3.0 Results and discussion 
3.1 Aptamer structure 
How aptamers recognise and bind to proteins and peptides expressed on the surface of 
cancer cells is not fully known but is thought to be a function of both their primary sequence 
and their subsequent three dimensional shapes. The sgc8 aptamer, from which sgc8c is 
derived is known to be taken into cells via receptor mediated endocytosis [22]. Computer 
modelling. using the online program OligoCalc [23] [24], has predicted that the sgc8c 
aptamer most likely forms a stem-and-loop type conformation from 5 possible structures 
(ΔG values ranging from 0.46 to -0.31 Kcal mol) as well as a possible complete random coil 
state. The proposed stem and loop conformation would maximise Watson-Crick base pairing 
and be the most stable; although this has never been experimentally determined (Figure 1 
and supplementary information). Therefore, before the metal complex [(1,10-
phenanthroline)(ethylenediamine)platinum(II)]2+ (PHENEN) was added to the aptamer, the 
aptamer’s tertiary structure was examined in solution using circular dichroism and 
Watergate 1H NMR spectroscopy. 
 
It is known that calf-thymus DNA adopts a typical B-type DNA conformation in solution [25], 
with a characteristic positive peak centred around 275 nm, a negative peak centred around 
240 nm and zero ellipticity around 258 nm, as shown in Figure 2. In comparison, the sgc8c 
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DNA aptamer displays a similar CD spectrum with a positive peak around 275 nm, which is 
indicative of the DNA aptamer strand possessing 10.4 bases per turn and adopting a B-type 
DNA conformation [25]. The characteristic negative peak at 240 nm of the B-type DNA is 
shown to be present but at a lower intensity and slightly higher wavelength, centred around 
250 nm. In place of the small negative peak arising at 228 nm for B-type DNA, a strong 
positive peak is observed for the sgc8c aptamer. This positive peak may be due to the 
increased amount of expected random coil (non-base-paired) and single stranded bases 
within the aptamer compared with calf-thymus DNA.. 
 
The three-dimensional structure of the aptamer and the conformation adopted are likely 
key to its molecular recognition properties and use as a drug delivery vehicle. Due to the 
variety of different environments present within the body (high/low salt concentration and 
pH) it was of interest to determine whether the aptamer changed structure under different 
conditions. Of particular importance is its structure in both high and low salt concentrations 
which represent the conditions found in blood serum (Cl- = 100 mM) and inside cells (Cl- < 
20 mM). The CD spectrum of the sgc8c aptamer was therefore examined in both pure water 
and PBS (Figure 3). Comparison of the spectra shows only a minimal change in conformation 
in each solution, which is important as any change could affect the performance of the 
aptamer. 
 
A number of protons are involved in Watson-Crick base pairing. When DNA is in the random 
coil state resonances for these protons are not observed due to exchange with the 
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deuterated solvent. When the protons are involved in Watson-Crick base pairing however, 
because they are locked in place, they are seen in Watergate 1H NMR in the region 
downfield of 10 ppm [16]. For the free sgc8c aptamer, a number of weak imino resonances 
are observed between 10 and 14 ppm (supplementary information). These resonances are 
weak because no resonances would be expected for the DNA bases in the loop region of the 
aptamer and also because the aptamer may be in dynamic equilibrium between a random 
coil state and the stem-and-loop conformation, with the equilibrium lying towards the 
random coil state. 
 
3.2 Aptamer binding by PHENEN 
The metal complex PHENEN (Figure 4) and other 1,10-phenanthroline containing platinum 
complexes have been known to intercalate into double helical DNA since the 1970s [26-29]. 
The X-ray crystal structure of PHENEN intercalation was first reported by Lippard in 1976 
[30], and a molecular model showing a 3D representation of a 1,10-phenanthroline-based 
platinum(II) complex intercalating in DNA is given in reference [18]. As a well-studied DNA 
intercalator, with modest cytotoxicity, PHENEN was therefore chosen as a simple model of a 
coordinately saturated amine platinum complex for this study. The next step was to 
therefore determine whether PHENEN is able to intercalate into the stem of the sgc8c 
aptamer and what effect intercalation had on the aptamer’s structure. 
Upon intercalation into DNA, the aromatic proton resonances of phenanthroline-based 
platinum complexes are known to shift significantly upfield in one dimensional 1H NMR 
spectra [18, 27, 28]. The 1H NMR of free PHENEN has four aromatic resonances between 8.0 
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and 9.0, ppm (Figure 5). The 1H NMR spectrum of the free aptamer is much more complex 
with considerable overlap of all the aromatic and H1’ proton resonances, which excludes 
individual assignment.  
 
The addition of one equivalent of PHENEN to the sgc8c aptamer has two effects. The 
PHENEN Hd and Hb resonances shift upfield by at least 0.65 ppm. The Ha and Hc resonances 
may also shift, but they are indistinguishable from the aptamer resonances and so their 
movement cannot be determined. As the concentration of phenanthroline complexes in 
solution increases, they are known to self-aggregate which has the effect of shifting the 
aromatic resonances upfield; although the degree of the shift is relatively small (about 0.3 
ppm for concentrations up to 30 mM) [31]. The large shift of the PHENEN Hd and Hb 
resonances by more than 0.6 ppm is therefore indicative of the metal complex intercalating 
into the stem of the sgc8c aptamer [29] [18, 28]. In previous work, intercalation of PHENEN 
into sequence specific oligonucleotides resulted in shifts of the metal complex proton 
resonances of between 0.5 and 0.9 ppm, consistent with our results with the sgc8c aptamer 
[28]. The second effect is an exchange broadening of the aptamer resonances. Binding of 
the PHENEN complex to the aptamer can be either slow, intermediate or fast on the NMR 
time scale. For either slow or fast binding kinetics only sharp resonances for the aptamer 
would be observed. The general broadening of the aptamer resonances upon PHENEN 
addition is indicative of intermediate exchange kinetics and further evidence of PHENEN 
binding to the aptamer [27]. 
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The binding of PHENEN to the sgc8c aptamer was also analysed by CD spectrophotometry. 
Aliquots of PHENEN were added to the sgc8c aptamer in 10 mM NaCl in 0.5 mole equivalent 
increments up to a ratio of 10-to-1 and the CD spectrum recorded at each step (Figure 6).  
 
The resulting spectra show significant changes in the sgc8c aptamer’s conformation upon 
the addition of PHENEN. A decrease in the peak intensity of both positive peaks and the 
negative peak is observed. As more PHENEN is added, further changes in the shape of the 
aptamer’s curve are observed. This includes a hypsochromic shift of the positive peak shown 
from 220 nm to a shorter wavelength; a total shift of 2.5 nm is observed after addition of 
ten PHENEN equivalents. In addition, the intense negative peak at 250 nm splits, forming 
two less intense negative peaks at 255 nm and 230 nm. The primary stages of this peak 
formation can be seen after addition of three equivalents of PHENEN. 
 
The observed reduction in peak intensity is consistent with binding of the PHENEN to the 
DNA, however, the overall change in the aptamers curve observed with increasing 
concentration of PEHENEN is indicative of a change to the secondary structure of the 
aptamer such as unwinding and lengthening of its stem region to accommodate the 
intercalation of multiple PHENEN molecules. As the CD curve of the aptamer also continues 
to change after the addition of more than one equivalent of PHENEN, then this is consistent 
with the occupancy of more than one binding site on the DNA by the platinum complex. 
Given the length of the stem and the nearest neighbour exclusion principle [29], it would be 
expected that the sgc8c aptamer stem could accommodate up to four PHENEN molecules at 
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a time. The continued changes in the aptamer’s CD spectrum at high PHENEN-to-aptamer 
ratios therefore suggests that the binding of the metal complex to the aptamer is in 
equilibrium with free PHENEN, with a continual shift to more drug being bound at high 
PHENEN concentrations. 
 
The change in the CD spectrum with increasing PHENEN concentration was then used to 
approximate the association constant of the metal complex binding to the aptamer. A plot 
of the ellipticity at 250 nm against PHENEN concentration (supplementary information) 
gives a typical binding curve which increases until approximately 7.5 equivalents of PHENEN 
has been added. From this, a binding constant (Kb) of 4.3 (± 0.5) x 10
4 M-1 was calculated. 
Previous studies have shown that PHENEN binds to double helical DNA with a Kb of ~10
4-106 
M-1 [26, 28] so the value obtained for sgc8c binding is consistent with what would be 
expected. 
To further confirm binding of PHENEN to the sgc8c aptamer via an intercalation mode, DNA 
melting experiments were performed using UV spectrophotometry [29]. The free sgc8c 
aptamer has a very low temperature of melting (Tm = 18.5 oC) which is consistent with the 
Watergate NMR experiments which suggested that the aptamer is in equilibrium between a 
random coil and stem-and-loop conformation, with the equilibrium shifted toward the 
random coil state.  
Addition of one equivalent of PHENEN increases the melting temperature to 29.5 oC. 
Addition of more PHENEN results in further increases in the melting temperature with a Tm 
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of 36.5 oC for two equivalents of PHENEN and a Tm of 46.5 oC after three equivalents of 
PHENEN.  
Normal double stranded DNA, such as short oligonucleotides and calf thymus DNA (ct-DNA) 
have melting points (without drug/complex) of around 60-70 oC [32-34]. A drug or metal 
complex that does not intercalate into DNA raises the DNA melting temperature by less than 
5 oC [35]. An intercalating platinum(II) complex in comparison has been shown to increase 
the melting temperature anywhere between 6 and 20 oC depending on the nature of the 
intercalating ligand and the DNA:metal complex ratio [32, 34-36]. 
The very large change in Tm is consistent with an intercalation mode of binding although the 
magnitude of the increase in Tm was unexpected (2.5-fold higher). If PHENEN were binding 
to the sgc8c aptamer via simple electrostatic attraction or groove binding then only a 
modest increase in Tm would be expected (< 5 oC). The much larger increase in Tm for the 
aptamer could be a function of its structure compared with double stranded 
oligonucleotides and ct-DNA. For both the oligonucleotides and ct-DNA, the Watson-Crick 
base pairing is largely intact; in fact usually only the terminal and adjacent bases on the end 
of the strands are unpaired. The result is an already highly stable structure, so the addition 
of an intercalating ligand can only have a relatively small effect. In contrast, because much 
of the sgc8c aptamer is most likely in a random coil state, the structure is quite unstable and 
therefore the addition of an intercalating ligand would be expected to have a significantly 
bigger effect on its structural stability. An effect that is consistent with the observed 
increase in Tm for sgc8C. 
3.3 Aptamer effect on PHENEN cytotoxicity and uptake 
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The effect of the sgc8c aptamer on the cytotoxicity of PHENEN was examined using the on-
target CCRF-CEM leukaemia cell line and the off-target ovarian carcinoma cell line A2780 
and its cisplatin-resistant derivative A2780/cp70 (Table 1). PHENEN has moderate activity in 
the CCRF-CEM and A2780/cp70 cell lines but is not able to overcome cisplatin resistance.  
 
The sgc8C aptamer alone is not cytotoxic to CCRF-CEM  cells and is poorly active in 
A2780/cp70, but appears to have some inherent cytotoxicity in the A2780 line. It is not clear 
why the aptamer has inherent cytotoxicity towards the non-target cells. It is possible that 
for these cells that it binds to different peptide/proteins compared with the CCRF-CEM 
target cells, and the binding of these peptides/proteins affects cell growth. Some aptamers 
have been shown to bind to specific cell receptors and in one case thioaptamers were 
developed that bind the primary receptor for hyaluronic acid [37]. As this receptor plays an 
important function in tumour growth, it is possible that sgc8c may also bind similar 
receptors on the ovarian cancer cells, which may be the cause of their inherent cytotoxicity. 
 
The binding of PHENEN to the sgc8c aptamer decreases the activity of the platinum complex 
significantly (P < 0.01). Of importance, the sgc8c aptamer has little effect on the cytotoxicity 
of PHENEN in the off-target ovarian cell lines (P = 0.076), which is not unexpected, but also 
decreased the cytotoxicity of PHENEN in the on-target cell line.  
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The loss of PHENEN activity when bound to the aptamer could arise for three different 
reasons: (1) the conformational changes made to the aptamer upon PHENEN binding means 
the aptamer is no longer able to recognise and bind leukaemia cells, (2) the PHENEN bound 
sgc8c aptamer recognises and binds leukaemia cells but they are not internalised by the cell 
and/or (3) the PHENEN bound sgc8c aptamer recognises, binds and is internalised by the 
cells, but the PHENEN is not released inside the cell and therefore can’t act to induce 
apoptosis. 
To determine which of the three possible reasons is responsible for the loss of cytotoxicity, 
cellular uptake experiments were conducted using the same three cell lines using the sgc8c 
aptamer and another aptamer with the reverse sequence of sgc8c. This second aptamer was 
examined as it should display no selectivity for the CCRF-CEM cells and therefore the uptake 
results for this aptamer can be used to help differentiate between a lack of cell recognition 
and surface trapped PHENEN bound aptamer complex. 
The cellular uptake result of PHENEN with the sgc8c aptamer demonstrates that in most 
cases the addition of the aptamer results in a decrease in the uptake of the metal complex. 
The only exception is at the 2 hour mark where the aptamer has no discernible ffect on 
PHENEN uptake in the A2780/cp70 line. Importantly, the decrease in cellular uptake 
increases over time such that after 4 hours the uptake of PHENEN in the on-target CCRF-
CEM line has dropped 19.5% and has dropped in the off-target A2780 and A2780/cp70 lines 
21.1 and 10.8%, respectively. 
When PHENEN is added to an aptamer with the reverse sequence of sgc8c (sequence given 
in supplementary information) a similar effect on the metal complex’s cytotoxicity and 
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uptake was observed. The reverse sequence aptamer decreases the cytotoxicity of PHENEN 
by 2.6-fold and the metal complex’s cellular uptake by 56%. 
 
4. Conclusions 
In this work we examined the utility of the T-cell leukaemia targeting DNA sgc8c aptamer as 
a simultaneous delivery vehicle and active targeting agent for the delivery of an amine-
coordinately saturated platinum anticancer complex. The sgc8c form a stem-and-loop type 
conformation although the equilibrium appears to be shifted more towards the random coil 
state. The metal complex PHENEN binds the sgc8c aptamer via an intercalative mode, which 
affects the sgc8c’s conformation. 
The sgc8c aptamer and the reverse sequence aptamer in vitro results taken together 
suggest that the decrease in PHENEN cytotoxicity in the on-target CCRF-CEM cell line is due 
to an inability of the sgc8c aptamer to recognise the leukaemia cell lines. If the PHENEN-
aptamer complex was still able to recognise and bind to the cells but remained trapped on 
the surface of the cells, then it would be expected that the determined cellular platinum 
content would be higher compared with the free PHENEN uptake. Instead, the results show 
that the platinum content of the cells decreases, as it does for the reverse aptamer which 
cannot recognise CCRF-CEM cells. 
If this interpretation of the results is correct and the PHENEN bound sgc8C aptamer has lost 
its ability to recognise leukaemia cells, then it is important to determine why this is the case. 
From the structural analysis of the sgc8c aptamer conformation the results indicated that it 
formed and stem-and-loop structure, but this structure was dynamic with an equilibrium 
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shifted more towards the random coil state. Binding of PHENEN to the aptamer occurs via 
intercalation which is a process known to lengthen and stiffen helical DNA and prevent 
strand separation. From these results we therefore hypothesise that the sgc8c aptamer 
recognises and binds leukaemia cells not in its preferred stem-and-loop conformation, but 
either binds from a random coil state and adopts a defined conformation upon binding the 
cell, or it exists in the stem-and-loop conformation but must unwind to then bind the 
leukaemia cells. When PHENEN is bound to the aptamer it stops either of these processes 
from occurring leading to reduced cytotoxicity and uptake of the metal complex now that it 
is sequestered within the aptamer. 
If this hypothesise is correct, then the results of this study can be used to design drug-
aptamer complexes that can still transport drugs whilst simultaneously actively targeting 
cancer cells. To do this a drug-aptamer complex needs to be developed where the binding 
of the drug to the aptamer neither locks, nor changes, the aptamers conformation, but is 
still bound with sufficient strength so as not to disassociate upon injection into the blood 
stream. Such a drug-aptamer complex may be possible when minor groove DNA binding 
drugs are used. DNA minor groove binding drugs are known to have good binding strengths 
to double helical DNA (up to 105 M-1), but do not significantly change or lock the DNAs 
conformation in the same way that intercalating drugs do.  
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56MESS (5,6-dimethyl-1,10-phenanthroline)(1S,2S-diaminocyclohexane)platinum(II) 
CD  circular dichroism 
ct-DNA  calf-thymus DNA 
ICP-MS  inductively coupled plasma mass spectrometry 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NOESY  nuclear overhauser effect spectroscopy 
PBS  phosphate buffered saline 
PHENEN (1,10-phenanthroline)(ethylenediamine)platinum(II) chloride 
SEM  standard error of the mean 
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Table 1. The in vitro cytotoxicity using growth inhibition assays of the sgc8c, PHENEN and 1 
PHENEN bound sgc8c aptamer complex after 24 hours of drug exposure, expressed as their 2 
inhibition concentration 50% (IC50) values in the on-targeted CCRF-CEM leukaemia cell line 3 
and the off-target ovarian carcinoma cell lines A2780 and A2780/cp70. 4 
Compound 
IC50 (µM) 
CCRF-CEM A2780 A2780/cp70 
cisplatin 0.57 ± 0.03 0.43 ± 0.05 5.60 ± 0.39 
sgc8c aptamer > 1000 6.59 ± 1.29 104.1 ± 48.0 
PHENEN 7.77 ± 0.37 0.89 ± 0.47 12.36 ± 1.93 
sgc8c + PHENEN 10.91 ± 0.51 2.26 ± 0.33 12.85 ± 3.98 
 5 
Table 2. The in vitro cellular uptake of PHENEN and PHENEN bound sgc8c aptamer into on-6 
target leukaemia CCRF-CEM cells and off-target ovarian carcinoma A2780 and A2780/cp70 7 
cells as determined by inductively coupled plasma mass spectrometry. 8 
Compound 
(10 µM) 
Incubation time 
(h) 
Uptake (pmol Pt/106 cells) 
CCRF-CEM A2780 A2780/cp70 
cisplatin 4 14.7 ± 0.5 48.7 ± 1.9 35.5 ± 2.4 
PHENEN 2 27.5 ± 1.8 165.3 ± 6.2 163.5 ± 2.0 
sgc8c + PHENEN 2 20.7 ± 1.2 126.2 ± 3.0 166.1 ± 24.0 
PHENEN 4 49.9 ± 1.0 265.6 ± 8.4 252.2 ± 5.3 
sgc8c + PHENEN 4 40.2 ± 0.8 209.1 ± 3.8 225.9 ± 11.8 
 9 
Table(s)
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Table 3.  The in vitro cytotoxicity and cellular uptake of PHENEN and PHENEN with a reverse 10 
sequence sgc8c aptamer into on-target leukaemia CCRF-CEM cells and off-target ovarian 11 
carcinoma A2780 and A2780/cp70 cells. 12 
Compound 
Incubation 
Time (h) 
IC50 (M) 
CCRF-CEM A2780 A2780/cp70 
Cisplatin 24 0.57 ± 0.03 0.43 ± 0.05 5.60 ± 0.39 
Aptamer 24 > 200  14.7 ± 4.1 55.0 ± 3.5 
PHENEN 24 7.77 ± 0.37 0.89 ± 0.47 12.36 ± 1.93 
PHENEN-reverse aptamer 24 5.78 ± 0.56 13.6 ± 2.1 > 200 
  Uptake (pmol/106 cells) 
PHENEN 2 55.6 ± 4.8 77.1 ± 4.8 16.0 ± 2.2 
PHENEN-reverse aptamer 2 27.0 ± 2.6 36.6 ± 2.3 6.38 ± 0.23 
PHENEN 4 135.2 ± 9.6 141.7 ± 7.2 23.0 ± 1.5 
PHENEN-reverse aptamer 4 59.3 ± 3.3 76.3 ± 3.7 9.07 ± 0.53 
 13 
 14 
   
Figure 1. The predicted structure (left) of the T-cell leukaemia targeting sgc8c aptamer, 
determined from computer modelling and showing the potential binding area of PHENEN into 
the aptamer’s double helical stem (the * indicates a base-pair mismatch) and a schematic 
diagram (right) showing the process of intercalation of PHENEN between base-pairs in double 
helical DNA. 
  
Figure(s)
Click here to download Figure(s): Figures and figure captions.docx
 Figure 2. A comparison of the measured circular dichroism spectra of free sgc8c DNA aptamer 
in water (orange, solid line) and calf-thymus DNA (purple, dashed line). Calf-thymus DNA is 
known to form a typical B-type DNA conformation and the similarity of the aptamer’s CD 
spectra is consistent with the formation of a B-type DNA conformation within a part of the 
aptamer. 
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Figure 3. The CD spectra of free sgc8c aptamer in water (orange, dashed line), 10 mM (blue, 
solid line) and 100 mM (green, dotted line) phosphate buffered saline showing that the 
aptamer retains its structure in all three environments. 
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Figure 4. The chemical structure of [(1,10-phenanthroline)(ethylenediamine)platinum(II)]2+ 
(PHENEN) showing the proton naming scheme used. Counter ions are omitted, but the general 
synthetic method produces a chloride salt of the complex. 
  
  
Figure 5.  The 1H NMR spectra (D2O, 20 mM PBS, 400 MHz) of (a) PHENEN, (b) sgc8c aptamer 
with the addition of one equivalent of PHENEN and (c) the free sgc8c aptamer, showing the 
upfield shift of the PHENEN Hd and Hb proton resonances, consistent with DNA intercalation. 
  
  
Figure 6. The circular dichroism spectra of the sgc8c aptamer in 20 mM PBS showing the free 
aptamer (dark blue) and its spectra upon the addition of PHENEN (0.5 to 10 mole equivalents). 
The arrows indicate the direction of change of the peaks. 
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Supplementary information 
Reverse aptamer sequence: 5’- AGA TTG GCA TGT CAT TAA AGG GCC GCC GCG TCG TCA ATC 
TA-3’ 
 
 
Figure S1. The predicted five possible conformations based on Watson-Crick pairing of the 
sgc8c DNA aptamer from computer modelling using OligoCalc [23]: available at 
www.basic.northwestern.edu/biotools/oligocalc.html. The ΔG values for each conformation 
going from left to right, top to bottom are: 0.46, 0.26, 0.20, -0.25 and -0.31. 
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Figure S2. The 1H Watergate NMR spectrum of the free sgc8c aptamer showing the weak 
imino protons which is indicative of Watson-Crick base pairing in the structure of the 
aptamer.  
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Figure S3. The binding curve of PHENEN to the sgc8c aptamer showing the change in 
ellipticity at 250 nm as determined by circular dichroism as 0 to 10 equivalents of the metal 
complex is added. 
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